Dr. Joshua K. Sabari

Cancer is nonpartisan. It touches everyone — cutting across religion, race, ethnicity, sexual orientation and socioeconomic status.

Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting.

The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.

Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about recent data from ASCO 2025.

Dr. Rita Mukhtar and Dr. Joshua K. Sabari discuss the role of ctDNA to guide surgical decision-making after neoadjuvant chemo in breast cancer treatment.

For patients with metastatic HR+/HER2— breast cancer, there were various trials to have come out of ASCO 2025 that are worth keeping your eye on.

Both non-small lung cancer and small cell lung cancer is a disease that now has various therapeutic options available, according to experts.

Dr. Joshua K. Sabari and Jackie Herigodt sat down to discuss the importance of knowing a patient beyond their cancer diagnosis.

The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs. Joshua K. Sabari and Manmeet Singh Ahluwalia.

Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.

Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.

Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology

Our longtime editor-in-chief offers advice to his successor while discussing the news and education CURE magazine provides for patients with cancer, families and caregivers.